2616.HK · CSTONE PHARMA-B
Hong Kong · RS rating 22 · As of 2026-10-14
| Price | 4.78 HKD |
|---|---|
| 1-day change | -4.0% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 9 / 44 / 31 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 18 / 15 |
| Industry group (rank) | Pharma & Biotech (30) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.3% |
| Market cap (USD) | $1.0B |